PRNewsWire
17 Dec 2025, 01:00 UTC · 42w ago
Verdict
Headline leans bullish. We score 6996.HK +0.80 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Malaysian National Pharmaceutical Regulatory Agency approved XPOVIO (selinexor) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
More positive than 79% of claims this week
XPOVIO is already approved in ten countries/regions in APAC and is included in national insurance schemes in five of those markets.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 54% of claims this week
Antengene expects XPOVIO to receive public insurance coverage in additional APAC markets moving forward.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company received regulatory approval in Malaysia to expand the indications for its drug XPOVIO, increasing its potential patient base.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13h ago
—
No price for 6996.HK right now — the quote feed didn't answer.
6996.HK chart →
